LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

LeMaitre Vascular Inc

Slēgts

SektorsVeselības aprūpe

86.93 -1.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

86.13

Max

88.15

Galvenie mērījumi

By Trading Economics

Ienākumi

3.6M

17M

Pārdošana

-3.2M

61M

P/E

Sektora vidējais

37.841

105.69

Dividenžu ienesīgums

0.88

Peļņas marža

28.441

Darbinieki

651

EBITDA

-1.7M

20M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+19.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.88%

2.37%

Nākamais dividenžu datums

2025. g. 4. dec.

Nākamais Ex dividenžu datums

2025. g. 20. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

24M

2B

Iepriekšējā atvēršanas cena

88.31

Iepriekšējā slēgšanas cena

86.93

Ziņu noskaņojums

By Acuity

50%

50%

185 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

LeMaitre Vascular Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. nov. 18:59 UTC

Galvenie tirgus virzītāji

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

2025. g. 17. nov. 23:40 UTC

Tirgus saruna

Gold Consolidates Amid Mixed Signals -- Market Talk

2025. g. 17. nov. 23:34 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025. g. 17. nov. 22:58 UTC

Tirgus saruna

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

2025. g. 17. nov. 22:46 UTC

Tirgus saruna

Risk Assets Set to Have a Strong 2026 -- Market Talk

2025. g. 17. nov. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q Rev $2.6B >TCOM

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q Adj EPS $3.87 >TCOM

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q EPS $4.02 >TCOM

2025. g. 17. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. nov. 21:40 UTC

Peļņas

James Hardie Industries 2Q Adj EPS 26c >JHX

2025. g. 17. nov. 21:40 UTC

Peļņas

James Hardie Industries 2Q Loss/Shr 10c >JHX

2025. g. 17. nov. 21:39 UTC

Peļņas

James Hardie Industries 2Q Sales $1.29B >JHX

2025. g. 17. nov. 21:38 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 21:38 UTC

Peļņas

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

2025. g. 17. nov. 21:10 UTC

Peļņas

XP Inc. 3Q EPS BRL2.47 >XP

2025. g. 17. nov. 21:10 UTC

Peļņas

XP Inc. 3Q Rev BRL4.67B >XP

2025. g. 17. nov. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

2025. g. 17. nov. 20:12 UTC

Tirgus saruna

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

2025. g. 17. nov. 20:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. nov. 20:09 UTC

Tirgus saruna

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

2025. g. 17. nov. 19:29 UTC

Tirgus saruna

Gold Slide Continues to Start Week -- Market Talk

2025. g. 17. nov. 19:16 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 18:20 UTC

Iegādes, apvienošanās, pārņemšana

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

2025. g. 17. nov. 16:45 UTC

Iegādes, apvienošanās, pārņemšana

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

2025. g. 17. nov. 16:16 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 16:15 UTC

Peļņas

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

2025. g. 17. nov. 15:40 UTC

Iegādes, apvienošanās, pārņemšana

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

2025. g. 17. nov. 15:22 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

2025. g. 17. nov. 15:19 UTC

Tirgus saruna

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Salīdzinājums

Cenas izmaiņa

LeMaitre Vascular Inc Prognoze

Cenas mērķis

By TipRanks

19.86% augšup

Prognoze 12 mēnešiem

Vidējais 106 USD  19.86%

Augstākais 120 USD

Zemākais 95 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi LeMaitre Vascular Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

4

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

78.565 / 91.76Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

185 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par LeMaitre Vascular Inc

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
help-icon Live chat